Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 28203

1.

Cooccurrences of Putative Endogenous Retrovirus-Associated Diseases.

Brütting C, Emmer A, Kornhuber ME, Staege MS.

Biomed Res Int. 2017;2017:7973165. doi: 10.1155/2017/7973165. Review.

PMID:
28326328
2.

Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy.

Reschke CR, Silva LF, Norwood BA, Senthilkumar K, Morris G, Sanz-Rodriguez A, Conroy RM, Costard L, Neubert V, Bauer S, Farrell MA, O'Brien DF, Delanty N, Schorge S, Pasterkamp RJ, Rosenow F, Henshall DC.

Mol Ther Nucleic Acids. 2017 Mar 17;6:45-56. doi: 10.1016/j.omtn.2016.11.002.

PMID:
28325299
3.

Validity and reliability of the multidimensional assessment of fatigue scale in Iranian patients with relapsing-remitting subtype of multiple sclerosis.

Behrangrad S, Kordi Yoosefinejad A.

Disabil Rehabil. 2017 Mar 21:1-5. doi: 10.1080/09638288.2016.1271024. [Epub ahead of print]

PMID:
28325094
4.

Quantitative Analysis of Uveitis Macular Edema in Multiple Sclerosis Patients Receiving Deep Posterior Sub-Tenon Triamcinolone Acetonide Injection.

Jovanović S, Šarenac Vulović T, Radotić F, Tončić Z, Živković M, Petrović N.

Ophthalmic Res. 2017 Mar 22. doi: 10.1159/000458157. [Epub ahead of print]

PMID:
28324879
5.

Bilateral Birdshot Retinochoroiditis and Retinal Astrocytoma.

Mamtora S, Wong Y, Bell D, Sandinha T.

Case Rep Ophthalmol Med. 2017;2017:6586157. doi: 10.1155/2017/6586157.

PMID:
28321351
6.

Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.

Bourne T, Waltz M, Casper TC, Kavak K, Aaen G, Belman A, Benson L, Candee M, Chitnis T, Graves J, Greenberg B, Gorman M, Harris Y, Krupp L, Lotze T, Mar S, Ness J, Olsen C, Roalstad S, Rodriguez M, Rose J, Rubin J, Schreiner T, Tillema JM, Kahn I, Waldman A, Barcellos L, Waubant E, Weinstock-Guttman B; US Network of Pediatric MS Centers..

J Neurol Sci. 2017 Apr 15;375:371-375. doi: 10.1016/j.jns.2017.02.041.

PMID:
28320170
7.

Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.

Noori-Zadeh A, Mesbah-Namin SA, Saboor-Yaraghi AA.

J Neurol Sci. 2017 Apr 15;375:203-208. doi: 10.1016/j.jns.2017.01.060.

PMID:
28320131
8.

Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.

Trenova AG, Slavov GS, Manova MG, Draganaova-Filipova MN, Mateva NG, Miteva LD, Stanilova SA.

Scand J Clin Lab Invest. 2017 Mar 20:1-6. doi: 10.1080/00365513.2017.1303843. [Epub ahead of print]

PMID:
28319417
9.

Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, Casanova B, Ouyang J, Bembeeva R, Haas J, Bader P, Snowden J, Farge D.

Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.40. [Epub ahead of print]

PMID:
28319075
10.

Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?

Adamczyk-Sowa M, Medrek A, Madej P, Michlicka W, Dobrakowski P.

J Immunol Res. 2017;2017:7904821. doi: 10.1155/2017/7904821.

11.

Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

Nguyen L, Lucke-Wold BP, Mookerjee S, Kaushal N, Matsumoto RR.

Adv Exp Med Biol. 2017;964:133-152. doi: 10.1007/978-3-319-50174-1_10.

PMID:
28315269
12.

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.

Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups..

Mult Scler. 2017 Mar 1:1352458517695468. doi: 10.1177/1352458517695468. [Epub ahead of print]

PMID:
28304217
13.

DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.

Yang L, Liu Z, Ren H, Zhang L, Gao S, Ren L, Chai Z, Meza-Romero R, Benedek G, Vandenbark AA, Offner H, Li M.

Metab Brain Dis. 2017 Mar 16. doi: 10.1007/s11011-017-9991-6. [Epub ahead of print]

PMID:
28303450
15.

Glial cell: a potential target for cellular and drug based therapy in various CNS diseases.

Ahmed S, Sultana Y, Gull A, Khuroo T, Aqil M.

Curr Pharm Des. 2017 Mar 16. doi: 10.2174/1381612823666170316124500. [Epub ahead of print]

PMID:
28302022
16.

Mitochondria-targeted antioxidants as a prospective therapeutic strategy for multiple sclerosis.

Fetisova EK, Chernyak BV, Korshunova GA, Muntyan MS, Skulachev VP.

Curr Med Chem. 2017 Mar 16. doi: 10.2174/0929867324666170316114452. [Epub ahead of print]

PMID:
28302008
17.

IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.

Muls N, Nasr Z, Dang HA, Sindic C, van Pesch V.

PLoS One. 2017 Mar 16;12(3):e0173780. doi: 10.1371/journal.pone.0173780.

18.

Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS).

Saposnik G, Sempere AP, Prefasi D, Selchen D, Ruff CC, Maurino J, Tobler PN.

Front Neurol. 2017 Mar 1;8:65. doi: 10.3389/fneur.2017.00065.

19.
20.

Further construct validity of the timed up and go test as a measure of ambulation in persons with multiple sclerosis.

Kalron A, Dolev M, Givon U.

Eur J Phys Rehabil Med. 2017 Mar 13. doi: 10.23736/S1973-9087.17.04599-3. [Epub ahead of print]

PMID:
28290192

Supplemental Content

Loading ...
Support Center